Experimental cancer combo aims to supercharge immune attack on tumors
NCT ID NCT03252938
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goal is to see if giving IMP321 in new ways—such as directly into tumors or the abdomen—is safe and feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMP321 (eftilagimod alfa) and avelumab
- What this could lead to
- If successful, this could point toward new ways to boost the immune system to fight advanced solid tumors.
- What could go wrong
- This is an early Phase 1 trial with a small number of participants, so it is too soon to know if the approach works. Side effects are possible, and the combination therapies may not be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH
Frankfurt, 60431, Germany
-
Helios Dr. Horst Schmidt Klinikum Wiesbaden
Wiesbaden, 65199, Germany
-
Helios Klinikum Bad Saarow
Bad Saarow, 15526, Germany
-
Hämatologisch Onkologische Praxis Eppendorf (HOPE)
Hamburg, 20249, Germany
-
Kliniken der Stadt Köln gGmbH, Studienzentrum der Lungenklinik, Krankenhaus Merheim
Cologne, 51109, Germany
-
Krankenhaus Nordwest
Frankfurt, 60488, Germany
-
Marienhospital Herne, Klinik der Ruhr Universität Bochum, Klinik für Urologie
Herne, 44625, Germany
-
Universität Gießen und Marburg GmbH
Giessen, 35392, Germany
-
Universitätsklinikum Essen
Essen, 45147, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
-
Universitätsklinikum Ulm, Early Clinical Trials Unit (ECTU)
Ulm, 89081, Germany
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, 55131, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can Lab-Grown tumor models predict the best therapy for each patient?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?